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Objective: Over 23 million people are affected by asthma in the United States and 262 million
individuals globally. Asthma, if poorly controlled, is associated with significant morbidity as
well as increased risk for mortality. Several complex inflammatory pathways and processes are
involved leading to an increase in immune cell activation. Curcumin, the active constituent found
in turmeric, has been studied in numerous in-vivo and in-vitro studies to generate antiinflammatory effects in pulmonary diseases. More recently, an increase in clinical data has
become available, and since the most recent review assessing the role of curcumin in pulmonary
disorders, additional clinical trials have been published. We provide the first meta-analysis
evaluating the efficacy of curcumin supplementation in asthma.

Methods: We searched PubMed and Google Scholar for eligible studies up to June 30, 2021,
using medical subject headings and keywords for asthma. Any clinical trial design, conducted in
humans, assessing the efficacy of curcumin on asthma related symptoms and lung functioning
were included. Two authors, using predefined criteria, independently screened, extracted data,
and assessed risk of bias from included studies using predefined criteria. Random effects metaanalysis was performed for each outcome, with effect size reported as mean difference (MD) or
as a standardized mean difference.

Results: 1,216 studies were screened, 8 included for review (n = 509) and adequate data from 3
trials (n = 203) included for meta-analysis. Most participants were of female sex (52.2%) and the
mean age (SD) of participants was 39.23 (14.7) years. The forced expiratory volume in one
second (FEV1%) improved with curcumin supplementation (3 studies; pooled MD = 3.70 (1.00,
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6.41), p= 0.007, I2=0%) compared to control. Efficacy of curcumin supplementation on asthma
symptoms more generally were discordant and safety data was only reported in two trials.

Conclusions: Supplementation with curcumin may provide small improvements in FEV1%,
however conclusions are limited by the small number of studies and sample sizes, poor
methodological quality, inconsistent reporting of asthma related outcomes and high risk of bias
of included studies. Additional, high-quality, human trials are needed to assess the efficacy of
curcumin supplementation more robustly in asthma.

3

Introduction:

Asthma is a prevalent immune mediated disorder often associated with sensitivities to
airborne environmental irritants. Globally, the World Health Organization (WHO) estimates 262
million people have asthma and an estimated 25 million individuals in the United States,
according to The Center for Disease Control and Prevention (CDC).1,2 Asthma is more prevalent
amongst females and direct and indirect costs result in an annual expenditure between $56 to $82
billion.2-4
Asthma’s pathophysiology is complex, involving several mechanistic pathways
ultimately leading to the interaction of Nuclear Factor kappa-light-chain-enhancer of activated
B-cells (NFκB) cross-linking with IgE. This cross-linking activates mast cells, basophils and
eosinophils causing a release of histamines and other inflammatory mediators such as c-reactive
protein (CRP), tumor necrosis factor-α (TNF-α) and, interleukins.5-7 These inflammatory
mediators result in the constriction of airways producing clinical symptoms of asthma such as
wheezing, breathlessness and frequent nighttime awakenings due to coughing.5
The Global Initiative for Asthma (GINA) utilizes clinical symptoms in addition to
spirometry testing to diagnose asthma and categorizes asthma by clinical phenotype with
further subclassification based on severity (intermittent, mild, moderate, and severe).8 Suspicion
for asthma can be confirmed by spirometry when the forced expiratory volume of air in one
second (FEV1) is able to increase by at least 12% following the use of a short acting
bronchodilating agent.8 The use of various bronchodilators, corticosteroids, anti-inflammatory,
and/or biologic agents are routinely used as standard of care therapies for asthma, however, the
use of complementary and integrative health (CIH) practices for asthma are also highly
prevalent. An estimated 58.5% of adults in the U.S. use CIH practices for asthma, and although
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data is sparse and varies by region, an estimated 27-76% of children with asthma also use some
form of CIH.9,10 In U.S. based adults, herbal therapies comprised 21% of the natural products
used for asthma, however, which herbal therapies are used specifically, is less certain.9
Curcuma longa (turmeric), a plant species native to tropical South Asia, has been
traditionally used as a medicinal herb for centuries in Ayurvedic and Chinese medicine.5,11 Its
rhizome is a common ingredient in many types of dishes such as curry, and Ng et al., suggested
regular consumption of curry-based meals were independently associated with improvements in
asthma after adjusting for gender, age, height, housing status, smoking, occupational exposure,
asthma/COPD history, dietary, and other dietary supplemental intake.12 The main constituent of
Curcuma longa, curcumin, has also routinely demonstrated anti-inflammatory effects in a variety
of health-related conditions.11,13,14 Recently, there has been an increasing amount of literature
available on the potential therapeutic role of curcumin for the treatment of pulmonary disorders
including asthma, however, reviews of the literature are largely limited to investigating its effects
from in-vivo or in-vitro models.5,11
Despite a recent 2017 comprehensive review assessing curcumin in pulmonary diseases,
only two clinical trials assessing its role in asthma were included, provided conflicting results,
and failed to include a 2010 randomized controlled trial.5,15 Given several clinical trials have
been published since then, the purpose of this study is to systematically review the literature and
provide the most up to date clinical evidence assessing the efficacy and safety of curcumin
supplementation in asthmatics. To our knowledge, we are also the first authors to meta-analyze
the effects of curcumin supplementation in asthma compared to controls.
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Methods:
This study followed the Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) guidelines.16 A protocol of this review was not prospectively registered.

Eligibility for inclusion:
Patients:
Review authors included all randomized controlled trials (RCTs) and quasi-RCTs
assessing the efficacy of curcumin supplementation for asthma. Studies were included if asthma
participants were diagnosed by a physician or met asthma diagnostic criteria by spirometry at
study entry. Primary study authors were contacted by email for any missing or unclear
information, however, studies were not excluded from narrative review if no response was
obtained, given the limited number of publications available. Conference abstracts of clinical
data was also included if sufficient data could be obtained. No restrictions were placed on age,
sex, or weight of participants; type of asthma; setting; or language of publication provided a
publication written in any language other than English could be sufficiently translated via
Google Translate.

Intervention:
No restrictions were placed on curcumin supplementation administered in any form
(capsule, powder, etc.) route (oral, parenteral, etc.), dose, or length of time. Given curcumin is
the main active constituent of turmeric, studies utilizing turmeric in any form, route, dose, or
length of treatment time were also included.
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Comparison:
Studies were eligible for inclusion if the intervention was compared to placebo, standard
of care for asthma, or an active comparator.

Outcomes:
Studies were included if they measured at least one of the following outcome measures of
interest: (1) asthma symptoms defined as the number of asthma exacerbations per week,
nocturnal symptoms or awakenings due to asthma per week, frequency of rescue medication(s)
used per week, number of daytime symptoms per week, and the total score on the Asthma
Control Test (ACT) or Asthma Quality of Life Questionnaire (AQLQ); (2) lung functioning
assessed by spirometry or peak flowmetry including the forced expiratory volume in one second
(FEV1), forced vital capacity (FVC), ratio of FEV1 to FVC (FEV1/FVC), or the peak expiratory
flow rate (PEFR); and (3) safety and tolerability of curcumin supplementation.

Exclusion criteria:
Studies were excluded if they: (1). were conducted in animals; (2). were in-vitro, prospective or
retrospective cohorts, cross-sectional, case-series, or case-control study designs; (3). unable to be
translated via Google Translate; (4). included participants with other respiratory conditions
(COPD, restrictive lung disease, pneumonia etc.); (5). did not report on any outcomes of interest
as previously listed.
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Search strategy:
We searched PubMed and the first 1,000 results in Google Scholar from inception until
June 2021 with the assistance of a university librarian trained in literature searches. Reference
lists of included studies as well as previous reviews were hand searched. ClinicalTrials.gov and
the International Clinical Trials Registry Platform Search Portal (ICTRP) were searched for
ongoing or completed trials. The International Prospective Register of Systematic Reviews
(PROSPERO) was searched for similar ongoing or recently completed systematic reviews
addressing our study objectives. The search strategy can be accessed in the accompanying
appendix at the end of the manuscript (appendix 1).

Data Collection:
Authors used Mendeley Desktop for literature search results and management of
screening results. Studies meeting inclusion criteria were entered into Review Manager
(RevMan) version 5.3 software to create risk of bias summaries, extract data from studies for
meta-analysis, and present results in forest plots if appropriate.17 Both authors screened titles and
abstracts independently, with disagreements settled via consensus between study authors. TG
and AS conducted all data extraction and data was inputted into RevMan5.3. Any disagreement
in extraction of data was settled via consensus. Data items collected can be seen in table 1.

Risk of Bias Assessment:
The Cochrane Collaboration’s Risk of Bias tool was used to evaluate the risk of bias in
seven selected domains included: 1) random sequence generation, 2) allocation concealment, 3)
blinding of participants and personnel, 4) blinding of outcome assessment, 5) incomplete
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outcome data, 6) selective reporting, and 7) other biases.18 Each domain of bias was rated as low
risk, unclear risk, or high risk of bias, respectively.

Data Analysis:
Due to the heterogeneity across study methodologies in addition to adequate data only
available for assessing FEV1%, a random-effects meta-analysis was used to derive pooled
weighted mean differences (WMD) with 95% confidence intervals (95% CI) using an inverse
variance model of post-intervention effects.19 Heterogeneity across studies was calculated using
the I2 statistic to assess heterogeneity between studies for study results. We considered an I2 of
0-24% as low heterogeneity, 25-49% as mild heterogeneity, 50-74% as high heterogeneity, and
I2>75% considered as extensive heterogeneity.20 Given the lack of available studies for metaanalysis, heterogeneity was not further explored by sensitivity analyses or sub-group analyses.
Furthermore, evidence for potential publication bias was not attempted given the paucity of data
available.

Results:
1,216 studies were identified through database and registry search strategy; 8 were
eligible for inclusion in the systematic review with 3 providing adequate data for meta-analysis
(Figure 1). Two studies were identified in ClinicalTrials.gov of which, one was published and
identified in our PubMed search, with another study currently in progress (NCT04353310). Two
additional ongoing studies were found in the ICTRP (IRCT20191221045837N3) and
IRCT20161226031584N2). No relevant reviews were identified in PROSPERO.
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Figure 1: Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram.
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Study characteristics:
Study characteristics can be seen in Table 1. Two studies were conducted in Bosnia and
Herzegovina,23,27 with one study each conducted in Egypt15, India26 Indonesia24, Iraq21, Brazil22,
and the United States of America.25 Four studies compared curcumin to placebo15, 22, 25, 27, five
compared curcumin added to standard of care/active comparator vs standard of care/active
comparator alone21, 23, 24, 26, 27, , two compared combination products containing curcumin to
placebo or control15,21, and one trial compared powdered whole turmeric to identical placebo.22 In
one study, data was only available by conference abstract, however, despite attempts at
contacting authors, further information was unable to be obtained.23 The longest trial length was
six-months22, with the shortest trial performed by Sutedijo et al, however, the exact length of the
study was unclear.24

Participant characteristics:
There was a total of n = 509 participants across 8 studies (n=203 included in metaanalysis) with a total of n = 240 in curcumin, n = 269 in control groups. Mean age (39.23 ± 14.7)
of participants was reported in six studies, and 52.2% of study participants from six studies were
female.

Risk of Bias in individual studies:
Summary of the risk of bias of included studies can be seen in Figure 2. One reference
was judged as having unclear risk of bias as it was published as a conference abstract only,
without an ability to contact abstract authors.23 Due to significant drop out after randomization,
one study was assessed as having high risk of bias for incomplete outcome data, and another
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failed to report data on ACT scores, frequency of rescue inhaler use, or dose of inhaled
corticosteroids. 22,25

Figure 2: Risk of bias summary: review
authors' judgements about each risk of bias
item for each included study

Effect of curcumin on lung functioning:
Adequate data for meta-analysis was only available for FEV1%, which improved with
the addition of curcumin relative to control (3 studies: MD = 3.7% (1.0, 6.4), P = 0.007, I2 =
0%). Data was available from one abstract, however, reported mean FEV1% between groups
were not incorporated into meta-analysis as it was unclear if standard deviations were reported
despite efforts made in contacting corresponding authors.23 Manarin et al., reported FEV1%
graphically with medians and interquartile ranges, with no statistically significant difference
between groups and was not incorporated into meta-analysis.22 Three studies (n=115) reported
FEV1 in liters however, heterogeneity in reporting FEV1 measures limited pooling results into
meta-analysis.21, 25, 26 Of these three studies, two found no statistically significant difference
between groups.21,25
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Figure 3: Forest plot for primary outcome comparing curcumin supplementation to controls. CI, confidence interval

Peak expiratory flow rate
Two studies (n = 93) evaluated effects of curcumin supplementation on peak expiratory
flow rate; one as a RCT and the other as a quasi-experimental study in hospitalized asthmatic
patients.15,24 Neither study found statistically significant differences between groups.

Effect of curcumin on asthma symptoms:
A lack of adequate data was reported to assess the effects of curcumin on asthma
symptoms and results are described narratively. Improvements in asthma symptoms are
conflicting; four studies (n = 347) were able to identify statistically significant improvements in
asthma symptoms compared to controls,15, 22, 23, 27,with two studies (n = 75) finding no
statistically significant improvements in asthma symptoms.25, 26 Asthma Control Test (ACT)
scores were reported in two studies25, 27 (n=165) with conflicting results, and one abstract which
found statistically significant improvements in the curcumin group compared to control.23

Daytime symptoms
Two studies (n=123) reported the effects of curcumin supplementation for daytime
symptoms with conflicting results.15, 26 One study found a median of four fewer daytime
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symptoms per week compared to placebo group (p<0.001)15, however, another found no
differences between curcumin or control groups in any symptom including difficulty breathing,
wheezing, cough, or chest tightness.26

Nocturnal symptoms
Two studies (n = 97) reported statistically significant reductions in nocturnal symptoms
relative to control groups.15,22 Houssen et al., found a median reduction of two nocturnal
awakenings per week compared to placebo (p<0.001),15 with another study finding no
statistically significant differences between groups in reductions of nighttime symptoms.26

Need for rescue inhaler
Two studies (n = 97) reported statistically significant reductions in the need for rescue
inhalers with the addition of curcumin relative to control15, 22, with one able to demonstrate a
median reduction of two fewer days per week of rescue inhaler use compared to placebo
(p<0.001).15 In the trial by Manarain et al, at baseline, over 20% of participants in the curcumin
group required daily use of rescue inhaler with none requiring daily rescue medication after sixmonths.22 At baseline, greater than 25% of control participants required daily use of rescue
inhaler, and greater than 20% still required daily use of rescue inhaler at six-months.22 Two
studies (n=75) did not find any differences between groups in reliance on rescue inhalers,
however, results were not readily available from one study despite attempts at contacting the
authors.25,26

Frequency of acute exacerbations
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The number of exacerbations per week was only recorded by one study which found a
median reduction of two exacerbations per week relative to control group (p<0.001).15

Safety of Curcumin:
Only two trials (n = 94) reported safety data with neither study revealing increased risk of
harm with curcumin.22,26

Discussion:
Clinical data from eight studies (n = 509) were included in this review, providing some
evidence of an effect on lung functioning as seen by a 4% increase in FEV1, as well as overall
improvements in asthma symptoms. These improvements build upon prior evidence highlighting
curcumin’s ability to inhibit inflammatory cytokines and upregulate anti-inflammatory immune
activation leading to a reduction of airway hyperresponsiveness and relaxation of smooth muscle
cells within the bronchopulmonary system.5, 7, 28
Heterogeneity in how asthma symptoms were reported by included studies prevented
pooling of results to provide a quantitative estimate for how much of an effect curcumin
supplementation can provide for specific asthma related symptoms (e.g., daytime symptoms,
nocturnal symptoms, reliance on rescue inhaler). Despite most studies suggesting improvements
in asthma related symptoms, the overall methodological quality of included studies was low,
with only two double blinded RCTs available, and most studies at unclear or high risk of bias. As
such, readers should interpret our findings with caution and three additional on-going clinical
trials (NCT04353310, IRCT20191221045837N3 and IRCT20161226031584N2) are likely to
impact our findings after data become available.
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Strengths:
This is the first review the study authors are aware of that provides a meta-analysis of
clinical data evaluating the effects of curcumin supplementation in asthma. We have included the
largest number of studies conducted in humans with asthma compared to previously conducted
reviews which were limited to only two studies.5,11 Additional strengths include a comprehensive
search strategy not limited to the English language and adherence to the PRISMA checklist.
Limiting assessments of lung function, asthma symptoms, and safety of curcumin
supplementation to randomized trials provided for more robust conclusions about the efficacy of
curcumin supplementation.

Limitations:
Our review is limited by the number of studies available, small sample sizes of included
studies, duration of follow up/length of treatment, inconsistencies in reporting of outcome
measures, and risk of bias of included studies. Two studies additionally utilized mixed products
and dosing strategies varied widely between 15mg – 2,200mg across studies.15,21 Additionally,
findings are further limited by a lack of sufficient data assessing the impact of curcumin
supplementation across a spectrum of asthma severities.

Implications/Recommendations for research:
We recommend future investigations to report on all lung functioning measures available
through spirometry and to report asthma symptoms in an identical and consistent manner
utilizing standardized asthma symptom questionnaires such as the ACT or AQLQ with total and
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sub-scores readily available. Future studies should address concerns around the paucity of data
available in children and adolescents as well as safety of curcumin supplementation. Although
curcumin in doses as high as 12,000mg appear to be safe with no severe adverse effects, future
studies should assess this in individuals being treated for asthma more specifically.29
Additionally, studies should utilize similar doses, dosing strategies, and formulations of
curcumin, examine the impact of curcumin across asthma severities, and improve upon the
methodological quality currently available.
Due to the hydrophobic and lipophilicity of curcumin, its bioavailability and absorption is
notoriously low, known to degrade at physiological pH and rapidly metabolized, limiting its
therapeutic effects.11,30 Chauhan et al., were able to demonstrate increased therapeutic efficacy,
via intranasal administration in a murine model of asthma, finding a reduction in inflammatory
signaling.31 However, additional research in humans is necessary to identify if intranasal
applications provide any advantage over oral supplementation for individuals with asthma.

Implications for clinical practice:
Based on the results from our review, the use of curcumin to provide clinical benefit in
asthma is likely minimal and recommending curcumin for asthma in clinical practice currently
cannot be made and further high-quality research is necessary. Consistency in the reporting of
lung functioning via spirometry as well as assessment of asthma symptoms are needed. It is still
unclear at which dose/dosing strategy is most effective, how much benefit is provided to children
or adolescents, if benefit is independent on asthma severity, and if benefits are sustained long
term without significant adverse effects. If patients are utilizing curcumin supplementation with
a perceived benefit, it is likely safe to continue supplementation as a dose escalation study of
17

curcumin was reported to be safe at an observed dosage of 12,000 mg in adults and adverse
events were not associated with a dose dependent response.29

Conclusions:
This is the first systematic review with meta-analysis that study authors are aware of
evaluating the efficacy of curcumin supplementation in humans with asthma. Limited evidence
suggests short-term improvement in lung functioning assessed by spirometry with curcumin
supplementation compared to control. Overall, asthma symptoms also seemed to improve,
however, improvements in lung functioning and asthma symptoms need to be interpreted with
caution due to the lack of adequate high-quality studies at low risk of bias. Recommendations for
use in clinical practice cannot be made at this time and additional research with consistencies in
outcome reporting, dosing, safety, length of follow up, and effects of curcumin supplementation
in children and adolescents are warranted.
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Table 1: Characteristics of studies assessing efficacy of curcumin supplementation for asthma in clinical trials
Author,
Year
Houssen
et al
201015

Location

Design

Egypt

RCT

Sample
size
n = 63

Kim et al.
201125

USA

Double Blind
RCT

n = 15

Abidi et
al. 201426

India

Open label
RCT

n = 60

Jusufovic
et al 2017
(abstract)23

Bosnia and
Herzegovina

N/A

n = 100

Sutedijo et
al 201824

Indonesia

Quasiexperimental
study

n = 30

Sample
Characteristics
Non-smoking adults
18-60 years old,
with at last 1-year of
chronic bronchial
asthma not
adequately
controlled with low
to moderate inhaled
corticosteroids
Adults 18-60 years
old with at least 1year of stable
persistent asthma,
FEV1 ≥ 60%, use of
low to moderate
inhaled
corticosteroids, and
allergic to dust
mites.
Non-smoking adults
18-55 years old
diagnosed with mild
to moderate
bronchial asthma
and improvements
in FEV1 ≥ 15%
after salbutamol
administration or
FEV1 between 6080%.
Non-smokers with
moderately
controlled asthma
on stable doses of
inhaled
glucocorticoids
Non-smokers, at
least 18 years old
diagnosed with an
acute asthma
exacerbation
requiring
hospitalization

Duration

Intervention

Control

Outcome Measures

4-weeks

Combination
product taken 3
times daily:
150mg
boswellic acid,
50mg licorice
extract, 15mg
curcumin (n=39)

Identical
placebo
capsule
(lactose)
taken 3 times
daily (n=24)

Improvements in number of exacerbations/wk,
daytime and nighttime symptoms/wk, need for rescue
medication/wk, FVC. All p<0.001 compared to
placebo.

3 months

Curcumin
1,000mg twice
daily (n=9)

Placebo (n=6)

Daytime symptoms/wk;
nocturnal
symptoms/wk;
need for rescue
medication/wk; FVC%;
FEV1%; PEFR;
Frequency of acute
exacerbations per wk,
month, or year.
Postbronchodilator
FEV1; ACT scores;
frequency of rescue
inhaler use; dose of
inhaled corticosteroids

4-weeks

Curcumin
500mg twice
daily added on
to standard of
care (n=37)

Standard of
Care only
(n=40)

Asthma symptoms
(dyspnea, wheezing,
cough, chest tightness,
nocturnal symptoms,
total symptom score);
pre-bronchodilator
FEV1; postbronchodilator FEV1

No statistically significant difference between groups
in improvement of clinical symptoms.

Curcumin
500mg twice
daily added to
inhaled
glucocorticoid
therapy (n=50)
Curcumin
550mg four
times daily
added to
standard of care
(n=15)

Inhaled
glucocorticoid
(n=50)

FEV1%, ACT, AQLQ

Curcumin improved FEV1% (p<0.001),
ACT(p<0.001), and AQLQ (p=0.014) scores

Standard of
care only
(n=15)

PEFR; length of
hospital stay

No statistically significant differences between groups
in PEF improvement, or length of hospital stay.

2 months

N/A

Results

No statistically significant difference between groups
for FEV1%, or PEFR.

No statistically significant difference in any outcome
between groups

Curcumin improved FEV1 measures compared to
placebo, all p<0.001.

FEV1: Forced Expiratory Volume in 1 second; FEV1%: Predicted Forced Expiratory Volume in 1 second; FVC: Forced Vital Capacity; PEFR: Peak Expiratory Flow Rate; ACT:
Asthma Control Test; AQLQ: Asthma Quality of Life Questionnaire; wk: week
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Table 1 Continued
Author,
Year
Jusufovic
et al
201927

Location
Bosnia and
Herzegovina

Design
Single blind
RCT

Sample
size
n = 150

Sample
Characteristics
Non-smoking adults
at least 18 years old
with moderate to
severe asthma
requiring moderate
doses of inhaled
glucocorticoids.

Duration

Intervention

Control

Outcome Measures

Results

3 months

Curcumin 500mg
twice daily added to
inhaled glucocorticoid
therapy (n=50)

Placebo
added to
inhaled
glucocorticoid
therapy
(n=50)

FEV1%, ACT, AQLQ

FEV1%, ACT and AQLQ improved in all groups.
Statistically significant improvements in FEV1%,
ACT, and AQLQ with curcumin compared to both
placebo and control group.

FEV1%; FEV1;
FEV1/FVC

No statistically significant differences between
groups for FEV1%, FEV1, or FEV1/FVC

Frequency of
respiratory symptoms;
nighttime awakenings;
use of rescue inhaler;
interference with
normal activity; FEV1

No difference between groups in frequency of
symptoms, FEV1, or interference with normal
activity. Curcumin improved frequency of
nighttime awakenings (p<0.001), decreased
frequency in use of rescue inhaler(p<0.0001), and
overall disease control (p<0.01).

Khadir
201921

Iraq

Open-Label
RCT

n = 40

Chronic bronchial
asthma

2 months

Manarin
201922

Brazil

Double Blind
RCT

n = 34

Children and
adolescents between
7-18 years of age
with persistent
asthma

6 months

Curcumin 750mg +
Piperine 5mg twice
daily added to
standard of care (n =
23)
Powdered Curcuma
longa 30mg/kg/day

Inhaled
glucocorticoid
group alone
(n=50)
Standard of
care only (n =
17)

Identical
placebo
(maltodextrin)

FEV1/FVC: FEV1 to FVC ratio
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Appendix 1: Search strategy
PubMed:
1. Asthma [MeSH]
2. Asthma* [tw]
3. Respiratory hypersensitivity [MeSH]
4. Wheez* [tw]
5. airway responsiveness [tw]
6. airway hyperreactivity [tw]
7. airway hyper-reactivity [tw]
8. Airway hyper-responsiveness [tw]
9. Bronchospasm [tw]
10. bronchial responsiveness [tw]
11. bronchial disorder [tw]
12. bronchial hyperreactivity [tw]
13. bronchial hyper-reactivity [tw]
14. lung function [tw]
15. ventilatory function [tw]
16. Pulmonary function [tw]
17. Respiratory function tests [MeSH]
18. FEV [tw]
19. FEF [tw]
20. FVC [tw]
21. PEF [tw]
22. PTF [tw]
23. Interluekin-4 [tw]
24. Interleukin-5 [MeSH]
25. IL-5 [tw]
26. IL5 [tw]
27. Interleukin-13 [MeSH]
28. IL-13 [tw]
29. IL13 [tw]
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30. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR
#17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29
31. Curcuma [MeSH]
32. Curcumin [MeSH]
33. Turmeric [tw]
34. Tumeric [tw]
35. Tetrahydrocurcumin [tw]
36. Curcum* [tw]
37. #31 OR #32 OR #33 OR #34 OR #35 OR #36
38. #30 AND #37
Google Scholar:
All words: Curcuma and Asthma
At least one word: Turmeric OR Curcuma OR Curcumin OR Lung Function OR Respiratory Hypersensitivity

Appendix 2: PRISMA checklist:

26

Section/topic

Reported on
page #

#

Checklist item

1

Identify the report as a systematic review, meta-analysis, or both.

1

2

Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and
interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic
review registration number.

2

Rationale

3

Describe the rationale for the review in the context of what is already known.

4

Objectives

4

Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and
study design (PICOS).

5

Protocol and registration

5

Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration
information including registration number.

6

Eligibility criteria

6

Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication
status) used as criteria for eligibility, giving rationale.

6-7

Information sources

7

Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the
search and date last searched.

8

Search

8

Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.

Study selection

9

State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the metaanalysis).

TITLE
Title
ABSTRACT
Structured summary

INTRODUCTION

METHODS

Figure 1,
Appendix 1
Figure 1,
8

Data collection process

10

Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and
confirming data from investigators.

8

Data items

11

List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.

6-7

Risk of bias in individual studies

12

Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or
outcome level), and how this information is to be used in any data synthesis.

12

Summary measures

13

State the principal summary measures (e.g., risk ratio, difference in means).

9

Synthesis of results

14

Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I 2) for each
meta-analysis.

9
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Section/topic

#

Checklist item

Reported
on page #

Risk of bias across studies

15

Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting
within studies).

12

Additional analyses

16

Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which
were pre-specified.

8-9

Study selection

17

Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each
stage, ideally with a flow diagram.

Study characteristics

18

For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and
provide the citations.

Risk of bias within studies

19

Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).

Figure 2

Results of individual studies

20

For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention
group (b) effect estimates and confidence intervals, ideally with a forest plot.

Figure 3

Synthesis of results

21

Present results of each meta-analysis done, including confidence intervals and measures of consistency.

Figure 3
12-13

Risk of bias across studies

22

Present results of any assessment of risk of bias across studies (see Item 15).

Figure 2
12

Additional analysis

23

Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).

Summary of evidence

24

Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key
groups (e.g., healthcare providers, users, and policy makers).

15-16

Limitations

25

Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of
identified research, reporting bias).

16-17

Conclusions

26

Provide a general interpretation of the results in the context of other evidence, and implications for future research.

18

27

Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the
systematic review.

19

RESULTS
Figure 1
11

N/A

DISCUSSION

FUNDING
Funding
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